Wei Lin 4

What Happened
Wei Lin, Chief Medical Officer of Revolution Medicines (RVMD), reported a sale of 2,073 shares on 2026-03-17 at $99.48 per share for proceeds of $206,223. The Form 4 filed on 2026-03-19 lists the disposition code S (sale) and indicates the transaction was made to satisfy tax withholding obligations.

Key Details

• Transaction date and price: 2026-03-17 — 2,073 shares sold at $99.48 each.
• Total proceeds: $206,223.
• Filing date: 2026-03-19 (timely filing).
• Footnote F1: Sale executed pursuant to a Rule 10b5-1 instruction letter adopted 12/23/2024 to satisfy tax withholding upon vesting of RSUs after 3/15/2025.
• Footnote F2: The filing notes beneficial ownership includes 62,050 RSUs.
• Shares owned after transaction: filing does not state a single total in the provided summary; it does indicate the beneficial ownership reported includes the 62,050 RSUs.

Context
This was a planned sale under a Rule 10b5-1 trading arrangement to cover tax withholding for RSU vesting, which is a common, prearranged mechanism and generally reduces the informational value of the sale as a signal about the insider’s view of the company.